Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomoda to report lung cancer diagnostic trial results in early 2010

This article was originally published in Clinica

Executive Summary

Biomoda has completed recruitment in a phase II study of its early-stage diagnostic for lung cancer, CyPath. The trial, which has enrolled over 500 patients with a history of heavy smoking, will now start analysing samples from already-diagnosed lung cancer patients. The Albuquerque, New Mexico company expects to have final data in the first half of 2010. CyPath is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. It is designed for routine screening of large populations. In the study, deep-lung sputum samples will be screened using both CyPath and traditional Pap staining, and patients will also have a CT scan – the current standard of care for lung cancer detection.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel